Philippe Bovy

USPTO Granted Patents = 13 (Patent Applications = 2)

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 40(Granted Patents)

Company Filing History:

Years Active: 2000-2011

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8063045 - Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity (2011-11-22),

2. 7659298 - Pyrazole derivatives and use thereof as orexin receptor antagonists (2010-02-09),

3. 7655663 - Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity (2010-02-02),

4. 7652021 - Compounds useful for DPP-IV enzyme inhibition (2010-01-26),

5. 7625929 - Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics (2009-12-01),

6. 7453010 - Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof (2008-11-18),

7. 7419974 - Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same (2008-09-02),

8. 7348327 - Compounds (2008-03-25),

9. 7030160 - Propanolaminotetralines, preparation thereof and compositions containing same (2006-04-18),

10. 6413984 - 8-(heterocyclylmethyl)quinoline derivatives for treating urinary incontinence (2002-07-02),

11. 6331549 - 1-aminoethylquinoline derivatives for treating urinary incontinence (2001-12-18),

12. 6200991 - Imidazole derivatives, preparation and therapeutic application thereof (2001-03-13),

13. 6063810 - 2-aminoethyl-benzofuran derivatives, preparation thereof and (2000-05-16),

Title: Philippe Bovy: Innovator in Pharmaceutical Chemistry

Introduction

Philippe Bovy is a notable inventor based in Mareil Marly, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of enzyme inhibitors and receptor antagonists. With a total of 13 patents to his name, Bovy's work has had a substantial impact on drug development.

Latest Patents

Among his latest patents, Bovy has developed fluoropyrrolidines that exhibit dipeptidyl peptidase enzyme inhibitory activity. This invention relates to new, potent DPP-IV enzyme inhibitors that contain fluorine atoms. Additionally, he has created pyrazole derivatives that serve as orexin receptor antagonists. This patent encompasses compounds that are effective in therapeutic applications, including their isomers, salts, and solvates.

Career Highlights

Philippe Bovy has worked with prominent companies in the pharmaceutical industry, including Sanofi-Aventis and Sanofi-Synthelabo. His experience in these organizations has allowed him to contribute to various innovative projects and advancements in drug formulation.

Collaborations

Bovy has collaborated with several professionals in his field, including Peter Aranyi and Sandor Batori. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality of his inventions.

Conclusion

Philippe Bovy's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in drug development and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents pending:

Please report any incorrect information to support@idiyas.com